Literature DB >> 36038291

STAT3 Inhibits Autocrine IFN Signaling in Type I Conventional Dendritic Cells.

Taylor T Chrisikos1,2, Yifan Zhou1, Laura M Kahn1,2, Bhakti Patel1, Nina L Denne1, Athena Brooks1, Li Shen3, Jing Wang3, Stephanie S Watowich4,2.   

Abstract

Type I conventional dendritic cells (cDC1s) are an essential Ag-presenting population required for generating adaptive immunity against intracellular pathogens and tumors. While the transcriptional control of cDC1 development is well understood, the mechanisms by which extracellular stimuli regulate cDC1 function remain unclear. We previously demonstrated that the cytokine-responsive transcriptional regulator STAT3 inhibits polyinosinic:polycytidylic acid [poly(I:C)]-induced cDC1 maturation and cDC1-mediated antitumor immunity in murine breast cancer, indicating an intrinsic, suppressive role for STAT3 in cDC1s. To probe transcriptional mechanisms regulating cDC1 function, we generated novel RNA sequencing datasets representing poly(I:C)-, IL-10-, and STAT3-mediated gene expression responses in murine cDC1s. Bioinformatics analyses indicated that poly(I:C) stimulates multiple inflammatory pathways independent of STAT3, while IL-10-activated STAT3 uniquely inhibits the poly(I:C)-induced type I IFN (IFN-I) transcriptional response. We validated this mechanism using purified cDC1s deficient for STAT3 or IFN signaling. Our data reveal IL-10-activated STAT3 suppresses production of IFN-β and IFN-γ, accrual of tyrosine phosphorylated STAT1, and IFN-stimulated gene expression in cDC1s after poly(I:C) exposure. Moreover, we found that maturation of cDC1s in response to poly(I:C) is dependent on the IFN-I receptor, but not the type II IFN receptor, or IFN-λ. Taken together, we elucidate an essential role for STAT3 in restraining autocrine IFN-I signaling in cDC1s elicited by poly(I:C) stimulation, and we provide novel RNA sequencing datasets that will aid in further delineating inflammatory and anti-inflammatory mechanisms in cDC1s.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36038291      PMCID: PMC9529896          DOI: 10.4049/jimmunol.2101104

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  49 in total

1.  A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.

Authors:  Kevin C Barry; Joy Hsu; Miranda L Broz; Francisco J Cueto; Mikhail Binnewies; Alexis J Combes; Amanda E Nelson; Kimberly Loo; Raj Kumar; Michael D Rosenblum; Michael D Alvarado; Denise M Wolf; Dusan Bogunovic; Nina Bhardwaj; Adil I Daud; Patrick K Ha; William R Ryan; Joshua L Pollack; Bushra Samad; Saurabh Asthana; Vincent Chan; Matthew F Krummel
Journal:  Nat Med       Date:  2018-06-25       Impact factor: 53.440

2.  Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses.

Authors:  Ruijie Liu; Aliaksei Z Holik; Shian Su; Natasha Jansz; Kelan Chen; Huei San Leong; Marnie E Blewitt; Marie-Liesse Asselin-Labat; Gordon K Smyth; Matthew E Ritchie
Journal:  Nucleic Acids Res       Date:  2015-04-29       Impact factor: 16.971

3.  Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway.

Authors:  Karim C El Kasmi; Amber M Smith; Lynn Williams; Geoffrey Neale; Athanasia D Panopoulos; Athanasia Panopolous; Stephanie S Watowich; Hans Häcker; Brian M J Foxwell; Peter J Murray
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

4.  Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells.

Authors:  A Knödler; S M Schmidt; A Bringmann; M M Weck; K M Brauer; T A W Holderried; A-K Heine; F Grünebach; P Brossart
Journal:  Leukemia       Date:  2008-11-13       Impact factor: 11.528

5.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Authors:  Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

6.  The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.

Authors:  Álvaro de Mingo Pulido; Kay Hänggi; Daiana P Celias; Alycia Gardner; Jie Li; Bruna Batista-Bittencourt; Eslam Mohamed; Jimena Trillo-Tinoco; Olabisi Osunmakinde; Reymi Peña; Alexis Onimus; Tsuneyasu Kaisho; Johanna Kaufmann; Kristen McEachern; Hatem Soliman; Vincent C Luca; Paulo C Rodriguez; Xiaoqing Yu; Brian Ruffell
Journal:  Immunity       Date:  2021-05-11       Impact factor: 43.474

7.  STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13.

Authors:  Huiyuan Zhang; Hongbo Hu; Nathaniel Greeley; Jin Jin; Allison J Matthews; Erika Ohashi; Mauricio S Caetano; Haiyan S Li; Xuefeng Wu; Pijus K Mandal; John S McMurray; Seyed Javad Moghaddam; Shao-Cong Sun; Stephanie S Watowich
Journal:  Nat Commun       Date:  2014-12-15       Impact factor: 14.919

8.  Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells.

Authors:  Yifan Zhou; Natalie Slone; Taylor T Chrisikos; Oleksandr Kyrysyuk; Rachel L Babcock; Yusra B Medik; Haiyan S Li; Eugenie S Kleinerman; Stephanie S Watowich
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

9.  Genomic analysis of LPS-stimulated myeloid cells identifies a common pro-inflammatory response but divergent IL-10 anti-inflammatory responses.

Authors:  Andrew Paul Hutchins; Yoshiko Takahashi; Diego Miranda-Saavedra
Journal:  Sci Rep       Date:  2015-03-13       Impact factor: 4.379

10.  cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity.

Authors:  Stephen T Ferris; Vivek Durai; Renee Wu; Derek J Theisen; Jeffrey P Ward; Michael D Bern; Jesse T Davidson; Prachi Bagadia; Tiantian Liu; Carlos G Briseño; Lijin Li; William E Gillanders; Gregory F Wu; Wayne M Yokoyama; Theresa L Murphy; Robert D Schreiber; Kenneth M Murphy
Journal:  Nature       Date:  2020-08-12       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.